Document Detail

Asthma treatment outcome in children is associated with vascular endothelial growth factor A (VEGFA) polymorphisms.
MedLine Citation:
PMID:  22519966     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Asthma is a common chronic disease characterized by airway inflammation and structural remodeling. Vascular endothelial growth factor (VEGF), a major regulator of angiogenesis, is elevated in asthma patients. VEGF contributes to airway responsiveness and remodeling. It has been shown that treatment of asthma patients decreases VEGF levels, and inhibition of VEGF diminishes asthma symptoms in mice. Therefore, polymorphisms in the vascular endothelial growth factor A (VEGFA) gene might be associated with asthma treatment response.
METHODS: This study enrolled 131 children with asthma treated with different therapies - specifically, the inhaled corticosteroid (ICS) fluticasone propionate or the leukotriene receptor antagonist (LTRA) montelukast. We performed an association analysis between improvement of lung function - assessed by measurement of the percentage of the predicted forced expiratory volume in 1 second (%predicted FEV(1)), the ratio between the FEV(1) and the forced vital capacity (FEV(1)/FVC) after 6 and 12 months of treatment, and asthma control after 12 months of treatment - and two polymorphisms, rs2146323 and rs833058, in the VEGFA gene.
RESULTS: Polymorphism rs2146323 A>C in VEGFA was associated with response to ICS therapy. Asthma patients with the AA genotype had a greater improvement in the %predicted FEV(1) than those with the AC or CC genotype (p = 0.018). Conversely, the AA genotype in rs2146323 was associated with uncontrolled asthma in patients regularly receiving LTRA therapy (p = 0.020) and a worse FEV(1)/FVC ratio in patients who episodically used LTRA therapy (p = 0.044). Furthermore, polymorphism rs833058 C>T was associated with treatment response to episodically used LTRA therapy. A subgroup of patients with the TT genotype had an improvement in the %predicted FEV(1), compared with no improvement in patients with the CT or CC genotype (p = 0.029).
CONCLUSIONS: Our results showed that treatment response to commonly used asthma therapies (ICS or LTRA) is associated with polymorphisms rs2146323 and rs833058 in VEGFA. With additional replication of this preliminary study, our findings could contribute to the development of individualized asthma therapy.
Mateja Balantic; Matija Rijavec; Maja Skerbinjek Kavalar; Stanislav Suskovic; Mira Silar; Mitja Kosnik; Peter Korosec
Related Documents :
8307916 - Ranitidine for the prevention of complications following endoscopic sclerotherapy for e...
2358736 - A prospective study of infrared coagulation, injection and rubber band ligation in the ...
3873106 - Long-term sclerotherapy of bleeding esophageal varices in patients with liver cirrhosis...
9605956 - Long-term prognosis of non-shunt operation for idiopathic portal hypertension.
19446156 - Differences in annual medication costs and rates of dosage increase between tumor necro...
12203076 - Simultaneous anus and bowel operation is preferable for anal fistula in crohn's disease.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Molecular diagnosis & therapy     Volume:  16     ISSN:  1179-2000     ISO Abbreviation:  Mol Diagn Ther     Publication Date:  2012 Jun 
Date Detail:
Created Date:  2012-05-31     Completed Date:  2012-11-19     Revised Date:  2013-05-16    
Medline Journal Info:
Nlm Unique ID:  101264260     Medline TA:  Mol Diagn Ther     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  173-80     Citation Subset:  IM    
University Clinic of Pulmonary and Allergic Diseases, Golnik, Slovenia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Acetates / therapeutic use
Androstadienes / therapeutic use
Anti-Asthmatic Agents / therapeutic use*
Asthma / drug therapy*,  genetics*,  physiopathology
Forced Expiratory Volume / drug effects
Polymorphism, Single Nucleotide
Quinolines / therapeutic use
Treatment Outcome
Vascular Endothelial Growth Factor A / genetics*
Reg. No./Substance:
0/Acetates; 0/Androstadienes; 0/Anti-Asthmatic Agents; 0/Quinolines; 0/Vascular Endothelial Growth Factor A; CUT2W21N7U/fluticasone; MHM278SD3E/montelukast

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  A Partitioning Deletion/Substitution/Addition Algorithm for Creating Survival Risk Groups.
Next Document:  Intrinsic Terahertz Plasmons and Magnetoplasmons in Large Scale Monolayer Graphene.